Insider transactions

Brian Levy

CIK 1277458 · Chief Medical Officer · last filed 2016-02-11

Brian Levy is a Chief Medical Officer who has filed 19 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for OCAT, was dated Feb 11, 2016. Across all open-market trades the lifetime net is +$60.0K, making them a net buyer over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
19
Lifetime Open-Market Net
$60.0K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

AERI price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Ocata Therapeutics, Inc. (OCAT) Delisted Director 0 — — $0 4 2016-02-11
AERIE PHARMACEUTICALS INC (AERI) Delisted Chief Medical Officer 16,313 $15.25 $248.8K $60.0K 3 2015-02-27
BAUSCH & LOMB INC (BOL) Delisted Vice President 2,715 — — $0 5 2007-08-16

Recent Filings

19 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-02-11 Ocata Therapeutics, Inc. (OCAT) Delisted Mixed −12,500 -$106.2K EDGAR
2016-01-04 Ocata Therapeutics, Inc. (OCAT) Delisted Grant (A) +1,250 $0 EDGAR
2015-11-04 — Disp (D) — $0
2015-10-01 Ocata Therapeutics, Inc. (OCAT) Delisted Grant (A) +1,250 $0 EDGAR
2015-09-10 Ocata Therapeutics, Inc. (OCAT) Delisted Grant (A) +10,000 $0 EDGAR
2015-02-27 AERIE PHARMACEUTICALS INC (AERI) Delisted Grant (A) +10,313 $0 EDGAR
2014-12-12 — Grant (A) — $0
2014-03-17 AERIE PHARMACEUTICALS INC (AERI) Delisted Grant (A) — $0 EDGAR
2013-12-13 — Grant (A) — $0
2013-11-01 AERIE PHARMACEUTICALS INC (AERI) Delisted Buy (P) +6,000 $60.0K EDGAR
Showing 1–10 of 19
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.